Company intelligence / Profile preview
Axonova Pharma
Mauritiusaxonova-pharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Axonova has developed a proprietary pipeline focused on novel small molecule drug candidates for neurodegenerative disorders. All known assets are in preclinical development. The company leverages local biodiversity to identify new bioactive compounds and licenses out assets for further clinical advancement. No clinical results have been published.
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Small molecules/chemical drugsNatural product-inspired compoundsBioactive ingredients from biodiversity sources
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Regional research partners in Mauritius/sub-Saharan Africa; specific names not disclosed
Beyond the preview
Go deeper on Axonova Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axonova Pharma.